InnoPharmax Inc.
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and… Read more
InnoPharmax Inc. (4172) - Net Assets
Latest net assets as of June 2025: NT$552.96 Million TWD
Based on the latest financial reports, InnoPharmax Inc. (4172) has net assets worth NT$552.96 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$595.85 Million) and total liabilities (NT$42.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$552.96 Million |
| % of Total Assets | 92.8% |
| Annual Growth Rate | 3.19% |
| 5-Year Change | 27.84% |
| 10-Year Change | N/A |
| Growth Volatility | 16.21 |
InnoPharmax Inc. - Net Assets Trend (2019–2024)
This chart illustrates how InnoPharmax Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for InnoPharmax Inc. (2019–2024)
The table below shows the annual net assets of InnoPharmax Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$602.85 Million | +26.77% |
| 2023-12-31 | NT$475.55 Million | +10.33% |
| 2022-12-31 | NT$431.00 Million | -18.91% |
| 2021-12-31 | NT$531.54 Million | +12.72% |
| 2020-12-31 | NT$471.57 Million | -8.48% |
| 2019-12-31 | NT$515.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to InnoPharmax Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32285700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.08 Billion | 178.45% |
| Other Comprehensive Income | NT$-437.00K | -0.07% |
| Other Components | NT$100.47 Million | 16.67% |
| Total Equity | NT$602.85 Million | 100.00% |
InnoPharmax Inc. Competitors by Market Cap
The table below lists competitors of InnoPharmax Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intiland Development Tbk
JK:DILD
|
$41.29 Million |
|
GiG Software p.l.c.
F:K0W
|
$41.29 Million |
|
Innoprise Plantations Bhd
KLSE:6262
|
$41.30 Million |
|
Trisul S.A
SA:TRIS3
|
$41.31 Million |
|
U-Tech Media Corp
TW:3050
|
$41.27 Million |
|
Neousys Technology Inc.
TWO:6922
|
$41.25 Million |
|
Evergreen Corp
NASDAQ:EVGR
|
$41.25 Million |
|
Nan Yang Dyeing & Finishing Co Ltd
TW:1410
|
$41.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InnoPharmax Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 475,547,000 to 602,845,000, a change of 127,298,000 (26.8%).
- Net loss of 99,290,000 reduced equity.
- New share issuances of 225,000,000 increased equity.
- Other comprehensive income increased equity by 315,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-99.29 Million | -16.47% |
| Share Issuances | NT$225.00 Million | +37.32% |
| Other Comprehensive Income | NT$315.00K | +0.05% |
| Other Changes | NT$1.27 Million | +0.21% |
| Total Change | NT$- | 26.77% |
Book Value vs Market Value Analysis
This analysis compares InnoPharmax Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.11x to 2.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$7.14 | NT$15.05 | x |
| 2020-12-31 | NT$6.08 | NT$15.05 | x |
| 2021-12-31 | NT$6.07 | NT$15.05 | x |
| 2022-12-31 | NT$4.97 | NT$15.05 | x |
| 2023-12-31 | NT$5.13 | NT$15.05 | x |
| 2024-12-31 | NT$6.19 | NT$15.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InnoPharmax Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -307.43%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.05x
- Recent ROE (-16.47%) is above the historical average (-16.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -17.06% | -103.54% | 0.14x | 1.16x | NT$-139.42 Million |
| 2020 | -9.31% | -32.07% | 0.20x | 1.44x | NT$-91.06 Million |
| 2021 | -17.49% | -193.44% | 0.09x | 1.05x | NT$-146.12 Million |
| 2022 | -23.94% | -354.17% | 0.06x | 1.14x | NT$-146.28 Million |
| 2023 | -14.89% | -153.74% | 0.09x | 1.10x | NT$-118.39 Million |
| 2024 | -16.47% | -307.43% | 0.05x | 1.05x | NT$-159.57 Million |
Industry Comparison
This section compares InnoPharmax Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InnoPharmax Inc. (4172) | NT$552.96 Million | -17.06% | 0.08x | $41.28 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |